{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-001783","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2023-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.033275+00:00","generated_at":"2026-06-17T22:29:29.120068+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MiNK Therapeutics reports Q4 net loss $7.8M; cash $19.6M at Dec 31, 2022","bullets":["Net loss for Q4 2022: $7.8M ($0.23/share) vs $5.8M ($0.18) in Q4 2021.","Full year 2022 net loss $28.0M ($0.83/share) vs $30.2M ($1.16) in 2021.","Cash and equivalents $19.6M at Dec 31, 2022, down from $38.9M at Dec 31, 2021.","Cash used in operations FY2022 $18.9M; R&D expense rose to $23.1M from $14.0M.","Clinical update for agenT-797 in solid tumors to be presented at AACR April 2023; expansion into NSCLC/gastric cancer in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-001783","json":"https://secwatch.observer/filing/0001171843-23-001783.json","markdown":"https://secwatch.observer/filing/0001171843-23-001783.md","text":"https://secwatch.observer/filing/0001171843-23-001783.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000117184323001783/0001171843-23-001783-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000117184323001783/f8k_032123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T22:29:29.120068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c2f2d1824b2011b0119eb4f25deb0df2843152da","claim":"MiNK Therapeutics, Inc. reported the year ended December 31, 2022 results: net income $28.0 million, EPS $0.83 per share.","evidence_excerpt":"Net loss for the year ended December 31, 2022, was $28.0 million, or $0.83 per share compared to $30.2 million and $1.16 per share for the year ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840229/000117184323001783/0001171843-23-001783-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"$28.0 million"},{"label":"EPS","value":"$0.83 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e5486ad77fcd5685f03380903e13df44377b6a88","claim":"MiNK Therapeutics, Inc. reported the quarter ended December 31, 2022 results: net income $7.8 million, EPS $0.23 per share.","evidence_excerpt":"Net loss for the quarter ended December 31, 2022, was $7.8 million or $0.23 per share, compared to a net loss for the same period of 2021 of $5.8 million or $0.18 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840229/000117184323001783/0001171843-23-001783-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Net income","value":"$7.8 million"},{"label":"EPS","value":"$0.23 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}